Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase mutant glioma.

Spino M, Kurz SC, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara CM, Frenster JD, Tateishi K, Wakimoto H, Jain R, Riina HA, Nicolaides T, Sulman EP, Cahill DP, Golfinos JG, Isse K, Saunders LR, Zagzag D, Placantonakis DG, Snuderl M, Chi AS.

Clin Cancer Res. 2018 Nov 5. pii: clincanres.2312.2018. doi: 10.1158/1078-0432.CCR-18-2312. [Epub ahead of print]

PMID:
30397180
2.

Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.

Wu CC, Jain R, Radmanesh A, Poisson LM, Guo WY, Zagzag D, Snuderl M, Placantonakis DG, Golfinos J, Chi AS.

AJNR Am J Neuroradiol. 2018 Oct;39(10):1814-1820. doi: 10.3174/ajnr.A5794. Epub 2018 Sep 6.

PMID:
30190259
3.

Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.

Blakeley JO, Grossman SA, Chi AS, Mikkelsen T, Rosenfeld MR, Ahluwalia MS, Nabors LB, Eichler A, Ribas IG, Desideri S, Ye X; Adult Brain Tumor Consortium.

Clin Cancer Res. 2018 Aug 21. doi: 10.1158/1078-0432.CCR-18-0110. [Epub ahead of print]

PMID:
30131387
4.

Genotype-targeted local therapy of glioma.

Shankar GM, Kirtane AR, Miller JJ, Mazdiyasni H, Rogner J, Tai T, Williams EA, Higuchi F, Juratli TA, Tateishi K, Koerner MVA, Tummala SS, Fink AL, Penson T, Schmidt SP, Wojtkiewicz GR, Baig A, Francis JM, Rinne ML, Batten JM, Batchelor TT, Brastianos PK, Curry WT Jr, Barker FG 2nd, Jordan JT, Iafrate AJ, Chi AS, Lennerz JK, Meyerson M, Langer R, Wakimoto H, Traverso G, Cahill DP.

Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8388-E8394. doi: 10.1073/pnas.1805751115. Epub 2018 Aug 6.

PMID:
30082399
5.

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.

Andronesi OC, Arrillaga-Romany IC, Ly KI, Bogner W, Ratai EM, Reitz K, Iafrate AJ, Dietrich J, Gerstner ER, Chi AS, Rosen BR, Wen PY, Cahill DP, Batchelor TT.

Nat Commun. 2018 Apr 16;9(1):1474. doi: 10.1038/s41467-018-03905-6.

6.

State of the Art Treatment and Surveillance Imaging of Glioblastomas.

Margiewicz S, Cordova C, Chi AS, Jain R.

Semin Roentgenol. 2018 Jan;53(1):23-36. doi: 10.1053/j.ro.2017.11.003. Epub 2017 Nov 20. No abstract available.

PMID:
29405952
7.

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.

Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT.

NPJ Precis Oncol. 2017;1. pii: 20. doi: 10.1038/s41698-017-0020-3. Epub 2017 Jun 12.

8.

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT.

Oncotarget. 2017 May 12;8(45):79298-79304. doi: 10.18632/oncotarget.17837. eCollection 2017 Oct 3.

9.

Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.

Teng J, Hejazi S, Hiddingh L, Carvalho L, de Gooijer MC, Wakimoto H, Barazas M, Tannous M, Chi AS, Noske DP, Wesseling P, Wurdinger T, Batchelor TT, Tannous BA.

Neuro Oncol. 2018 Apr 9;20(5):642-654. doi: 10.1093/neuonc/nox198.

PMID:
29099956
10.

Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2.

Modrek AS, Golub D, Khan T, Bready D, Prado J, Bowman C, Deng J, Zhang G, Rocha PP, Raviram R, Lazaris C, Stafford JM, LeRoy G, Kader M, Dhaliwal J, Bayin NS, Frenster JD, Serrano J, Chiriboga L, Baitalmal R, Nanjangud G, Chi AS, Golfinos JG, Wang J, Karajannis MA, Bonneau RA, Reinberg D, Tsirigos A, Zagzag D, Snuderl M, Skok JA, Neubert TA, Placantonakis DG.

Cell Rep. 2017 Oct 31;21(5):1267-1280. doi: 10.1016/j.celrep.2017.10.009.

11.

Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma.

Cordova C, Chi AS, Chachoua A, Kondziolka D, Silverman JS, Shepherd TM, Jain R, Snuderl M.

J Thorac Oncol. 2017 Nov;12(11):e188-e190. doi: 10.1016/j.jtho.2017.07.029. No abstract available.

12.

Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.

Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W Jr, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto H.

Int J Cancer. 2017 Dec 1;141(11):2348-2358. doi: 10.1002/ijc.30929. Epub 2017 Aug 26.

PMID:
28801914
13.

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.

Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS.

PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.

14.

T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.

Patel SH, Poisson LM, Brat DJ, Zhou Y, Cooper L, Snuderl M, Thomas C, Franceschi AM, Griffith B, Flanders AE, Golfinos JG, Chi AS, Jain R.

Clin Cancer Res. 2017 Oct 15;23(20):6078-6085. doi: 10.1158/1078-0432.CCR-17-0560. Epub 2017 Jul 27.

15.

Identification of more potent imipridones, a new class of anti-cancer agents.

Chi AS.

Cell Cycle. 2017;16(17):1566-1567. doi: 10.1080/15384101.2017.1355171. Epub 2017 Jul 27. No abstract available.

16.

The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.

Tateishi K, Higuchi F, Miller JJ, Koerner MVA, Lelic N, Shankar GM, Tanaka S, Fisher DE, Batchelor TT, Iafrate AJ, Wakimoto H, Chi AS, Cahill DP.

Cancer Res. 2017 Aug 1;77(15):4102-4115. doi: 10.1158/0008-5472.CAN-16-2263. Epub 2017 Jun 16.

17.

Non-contrast MRI diagnosis of adhesive capsulitis of the shoulder.

Chi AS, Kim J, Long SS, Morrison WB, Zoga AC.

Clin Imaging. 2017 Jul - Aug;44:46-50. doi: 10.1016/j.clinimag.2017.04.002. Epub 2017 Apr 7.

PMID:
28410478
18.

Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma.

Chi AS, Cahill DP, Larvie M, Louis DN.

N Engl J Med. 2016 Dec 15;375(24):2381-2389. No abstract available.

PMID:
27974037
19.

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.

Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER.

J Neurooncol. 2017 Feb;131(3):603-610. doi: 10.1007/s11060-016-2332-5. Epub 2016 Nov 16.

PMID:
27853960
20.

GPR133 (ADGRD1), an adhesion G-protein-coupled receptor, is necessary for glioblastoma growth.

Bayin NS, Frenster JD, Kane JR, Rubenstein J, Modrek AS, Baitalmal R, Dolgalev I, Rudzenski K, Scarabottolo L, Crespi D, Redaelli L, Snuderl M, Golfinos JG, Doyle W, Pacione D, Parker EC, Chi AS, Heguy A, MacNeil DJ, Shohdy N, Zagzag D, Placantonakis DG.

Oncogenesis. 2016 Oct 24;5(10):e263. doi: 10.1038/oncsis.2016.63.

21.

Current Perspectives on Imaging for Systemic Lupus Erythematosus, Systemic Sclerosis, and Dermatomyositis/Polymyositis.

Kolasinski SL, Chi AS, Lopez-Garib AJ.

Rheum Dis Clin North Am. 2016 Nov;42(4):711-732. doi: 10.1016/j.rdc.2016.07.007. Epub 2016 Sep 9. Review.

PMID:
27742023
22.

In Reply.

Fathi AT, Chi AS.

Oncologist. 2016 Aug;21(8):1026. doi: 10.1634/theoncologist.2016-0138. No abstract available.

23.

Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.

Jafari-Khouzani K, Loebel F, Bogner W, Rapalino O, Gonzalez GR, Gerstner E, Chi AS, Batchelor TT, Rosen BR, Unkelbach J, Shih HA, Cahill DP, Andronesi OC.

Neuro Oncol. 2016 Nov;18(11):1569-1578. Epub 2016 Jul 5.

24.

Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma.

Ho AL, Koch MJ, Tanaka S, Eichler AF, Batchelor TT, Tanboon J, Louis DN, Cahill DP, Chi AS, Curry WT Jr.

J Clin Neurosci. 2016 Sep;31:99-105. doi: 10.1016/j.jocn.2016.02.019. Epub 2016 Jun 6.

PMID:
27279154
25.

Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.

Tateishi K, Iafrate AJ, Ho Q, Curry WT, Batchelor TT, Flaherty KT, Onozato ML, Lelic N, Sundaram S, Cahill DP, Chi AS, Wakimoto H.

Clin Cancer Res. 2016 Sep 1;22(17):4452-65. doi: 10.1158/1078-0432.CCR-15-2274. Epub 2016 Apr 13.

26.

Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.

Gainor JF, Chi AS, Logan J, Hu R, Oh KS, Brastianos PK, Shih HA, Shaw AT.

J Thorac Oncol. 2016 Feb;11(2):256-60. doi: 10.1016/j.jtho.2015.10.010. Epub 2015 Dec 18.

27.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS.

Oncologist. 2016 Feb;21(2):214-9. doi: 10.1634/theoncologist.2015-0342. Epub 2016 Feb 1.

28.

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JJ, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MVA, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP.

Cancer Cell. 2015 Dec 14;28(6):773-784. doi: 10.1016/j.ccell.2015.11.006.

29.

Association of Gluteus Medius and Minimus Muscle Atrophy and Fall-Related Hip Fracture in Older Individuals Using Computed Tomography.

Chi AS, Long SS, Zoga AC, Parker L, Morrison WB.

J Comput Assist Tomogr. 2016 Mar-Apr;40(2):238-42. doi: 10.1097/RCT.0000000000000341.

PMID:
26571058
30.

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.

Andronesi OC, Loebel F, Bogner W, Marjańska M, Vander Heiden MG, Iafrate AJ, Dietrich J, Batchelor TT, Gerstner ER, Kaelin WG, Chi AS, Rosen BR, Cahill DP.

Clin Cancer Res. 2016 Apr 1;22(7):1632-41. doi: 10.1158/1078-0432.CCR-15-0656. Epub 2015 Nov 3.

31.

Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Nahed BV, Redjal N, Brat DJ, Chi AS, Oh K, Batchelor TT, Ryken TC, Kalkanis SN, Olson JJ.

J Neurooncol. 2015 Dec;125(3):609-30. doi: 10.1007/s11060-015-1910-2. Epub 2015 Nov 3. Review.

PMID:
26530264
32.

Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.

Blakeley JO, Grossman SA, Mikkelsen T, Rosenfeld MR, Peereboom D, Nabors LB, Chi AS, Emmons G, Garcia Ribas I, Supko JG, Desideri S, Ye X.

J Neurooncol. 2015 Oct;125(1):123-31. doi: 10.1007/s11060-015-1876-0. Epub 2015 Aug 19.

33.

Prevalence and pattern of gluteus medius and minimus tendon pathology and muscle atrophy in older individuals using MRI.

Chi AS, Long SS, Zoga AC, Read PJ, Deely DM, Parker L, Morrison WB.

Skeletal Radiol. 2015 Dec;44(12):1727-33. doi: 10.1007/s00256-015-2220-7. Epub 2015 Aug 11.

PMID:
26260535
34.

Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.

Nigim F, Cavanaugh J, Patel AP, Curry WT Jr, Esaki S, Kasper EM, Chi AS, Louis DN, Martuza RL, Rabkin SD, Wakimoto H.

J Neuropathol Exp Neurol. 2015 Jul;74(7):710-22. doi: 10.1097/NEN.0000000000000210.

35.

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY.

Neuro Oncol. 2015 Jun;17(6):862-7. doi: 10.1093/neuonc/nou350. Epub 2015 Jan 7. Erratum in: Neuro Oncol. 2015 Dec;17(12):1650.

36.

Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.

Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT.

J Thorac Oncol. 2015 Feb;10(2):232-6. doi: 10.1097/JTO.0000000000000455.

37.

Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.

Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT.

J Neurooncol. 2015 Feb;121(3):627-34. doi: 10.1007/s11060-014-1680-2. Epub 2014 Dec 13.

38.

Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.

Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS.

J Neurooncol. 2015 Feb;121(3):557-63. doi: 10.1007/s11060-014-1667-z. Epub 2014 Nov 20.

39.

Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.

Chen YB, Batchelor T, Li S, Hochberg E, Brezina M, Jones S, Del Rio C, Curtis M, Ballen KK, Barnes J, Chi AS, Dietrich J, Driscoll J, Gertsner ER, Hochberg F, LaCasce AS, McAfee SL, Spitzer TR, Nayak L, Armand P.

Cancer. 2015 Jan 15;121(2):226-33. doi: 10.1002/cncr.29023. Epub 2014 Sep 9.

40.

Brain tumor cells in circulation are enriched for mesenchymal gene expression.

Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA.

Cancer Discov. 2014 Nov;4(11):1299-309. doi: 10.1158/2159-8290.CD-14-0471. Epub 2014 Aug 19.

41.

Case 8-2014: A man with headache, vomiting, and diplopia.

Cho TA, Chi AS, Schaefer PW.

N Engl J Med. 2014 Jun 26;370(26):2545. doi: 10.1056/NEJMc1404375. No abstract available.

42.

Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.

Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE.

Cell. 2014 Apr 24;157(3):580-94. doi: 10.1016/j.cell.2014.02.030. Epub 2014 Apr 10.

43.

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS.

Clin Cancer Res. 2014 Jun 1;20(11):2898-909. doi: 10.1158/1078-0432.CCR-13-3052. Epub 2014 Apr 8.

44.

Case records of the Massachusetts General Hospital. Case 8-2014. A 29-year-old man with headache, vomiting, and diplopia.

Cho TA, Chi AS, Schaefer PW, Louis DN.

N Engl J Med. 2014 Mar 13;370(11):1049-59. doi: 10.1056/NEJMcpc1214216. No abstract available. Erratum in: N Engl J Med. 2014 May 15;370(20):1962.

PMID:
24620869
45.

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.

Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19059-64. doi: 10.1073/pnas.1318022110. Epub 2013 Nov 4.

46.

Is there a role for bevacizumab in the treatment of glioblastoma?

Chi AS, Chamberlain MC.

Oncologist. 2013;18(10):1080-2. doi: 10.1634/theoncologist.2013-0296. Epub 2013 Sep 20. No abstract available.

47.

Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.

Taylor JW, Chi AS, Cahill DP.

Oncology (Williston Park). 2013 Jun;27(6):504-14. Review.

48.

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.

Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK.

Neuro Oncol. 2013 Aug;15(8):1079-87. doi: 10.1093/neuonc/not082. Epub 2013 Jul 4.

49.

An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.

Rheinbay E, Suvà ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, Louis DN, Kasif S, Chi AS, Bernstein BE.

Cell Rep. 2013 May 30;3(5):1567-79. doi: 10.1016/j.celrep.2013.04.021. Epub 2013 May 23.

50.

BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults.

Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN.

J Clin Oncol. 2013 May 10;31(14):e233-6. doi: 10.1200/JCO.2012.46.0220. Epub 2013 Apr 1. No abstract available.

PMID:
23547069

Supplemental Content

Support Center